Cardiovascular Medication Market Grows
(PRLEAP.COM) New York, June 14, 2005 — The worldwide market for prescription cardiovascular medications, which topped $75 billion in 2004, will surpass the $100 billion mark by 2008, according to a new report released today from Kalorama Information. However, growth in the market is uneven—certain therapeutic classes are on the decline while some niche areas show double-digit annual growth.
“The aging population is driving the cardiovascular market forward as a whole,” notes Mary Anne Crandall, the principal author of the study, “But it’s the new drugs and, particularly, new combination products that are changing clinical practice and providing the major opportunities for manufacturers.”
The study examined eight major segments of the cardiovascular market, including cardiac glycosides and positive inotropic agents, antihypertensives, antiarrhythmics, vasodilators and peripheral vasodilators, antihyperlipidemics, blood modifiers, diuretics, and other cardiovascular drugs. In addition, the report details epidemiology and demographics, covers major trends—such as OTC statins, combination product development, and potentially new approaches to hypertension—and provides competitive market share for the major players in each segment.
Priced at $3,500, The Worldwide Market for Prescription Cardiovascular Drugs can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1077786.html. It is also available at MarketResearch.com.
About Kalorama Information
Kalorama Information, an imprint of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Steven Heffner at 212-807-2634 or sheffner@kaloramainformation.com, or visit www.KaloramaInformation.com.
About MarketResearch.com


